We assessed whether pro-substance P (ProSP)was associated with poor prognosis after acute myocardial infarction(AMI), to identify novel pathophysiological mechanisms.
Introduction
Over the last few decades, the treatment of acute myocardial infarction has improved the prognosis of patients substantially, with introduction of thrombolysis, percutaneous coronary intervention, beta-blockers, ACE inhibitors and angiotensin receptor antagonists, statins, anti-platelet agents (such as aspirin and ADP receptor antagonists) and aldosterone
antagonists. There is a need to identify new pathways that may affect outcomes post infarction.
Subtance P (SP) and the neurokinins belong to the tachykinin family and are widely distributed in the central and peripheral nervous system (1) . Low levels are present in myocardium, and mainly in nerve fibres (1) . SP plays a role in nociception, inflammation, plasma extravasation, platelet and leukocyte aggregation in post-capillary venules, and leukocyte chemotactic migration through vessel walls (1) . Neurokinin (NK) receptors are mainly present in coronary vessels and intracardiac ganglia, and not on ventricular or atrial myocardium (2) . A direct action on the NK1 receptor in coronary arteries may cause NOmediated vasodilatation (1) , although this effect may be impaired in patients with coronary artery disease (3), leading to a dominant NK2 mediated vascoconstriction. SP and neurokinin A are negatively inotropic and chronotropic, acting via cholinergic neurons (2) . In contrast, NK1 antagonists improve inotropy and lusitropy in rat myocardial infarction (AMI) models whilst SP attenuates the positive inotropic effect of norepinephrine (4) . SP (via the NK1 receptor) has been implicated in myocardial stunning post-AMI in guinea pigs (5) .
SP is also expressed in platelets, has a pro-aggregatory effect on platelets (6) . Furthermore, NK1 receptor inhibition reduces thrombus formation. Administration of a NK1 receptor antagonist reduced fibrinous adhesion formation and increased tissue plasminogen 6 activator mRNA and activity, suggesting a role of SP in fibrinolysis (7) . SP also strengthens the clot formed in blood, an effect that may be mediated via leucocytes and the magnitude of which is dependent on full length or truncated NK1 receptor isoform expression (8) .
Myocardial (9) and pulmonary (10) SP has been observed to be increased in animal models of AMI suggesting a role in AMI. Investigations in man have been hampered by the very short half life of SP (12 min) (11) and there are no large studies examining the role of SP in AMI. The recent development of an assay for stable protachykinin A (ProSP) which is a surrogate for labile SP (12) , has enabled studies on the role of this tachykinin system in human disease. We therefore investigated the potential role of SP in AMI, by measuring ProSP and studying its association with major adverse cardiac events (MACE) such as death, heart failure (HF) or readmission with AMI (re-AMI). Detection (CHAID, analysis performed using SPSS), which detects which biomarker has the strongest interaction with the dependent variable in step-wise analysis.
Methods

Results
Patient Characteristics
The characteristics of the study population are shown in Table 1 , according to ProSP quartiles. Patients with higher ProSP levels were older, female, with more having past histories of hypertension, IHD, diabetes, HF. They had higher GRACE scores, NTproBNP and glucose levels and lower ejection fractions and eGFR.
Correlation analysis
Spearman correlation analysis (r s ) showed ProSP was significantly correlated to age (0.521), eGFR (-0.555), diastolic BP (-0.178), NTproBNP (0.428), wall motion score index (0.173) and heart rate (0.172) (all P<0.0005). ProSP was not correlated to troponin or peak creatine kinase levels.
A general linear model with 2000 bootstrap samples showed eGFR, age and Killip class above 1 as independent predictors of ProSP level (Table 2) .
Day curves for ProSP
Sequential plasma sampling over 5 days was available for 110 patients, of which 29 had a MACE within 2 years. Figure 1 demonstrates the plasma profile along with a general linear model with repeated measures that shows significant changes in ProSP over time (p<0.001), and higher levels in those with MACE p<0.03). In post-hoc testing, ProSP levels on day 1 was higher than days 3, 4 or 5 (p<0.001, 0.004 and 0.002 respectively, Bonferroni corrected for multiple comparisons). ProSP levels on days 1 and 2 were similar. There was no statistically significant interaction of the time profile of ProSP with MACE.
Survival analysis
During follow-up over 2 years, patients with elevated ProSP levels (log 10 transformed and standardised by 1 SD) had more MACE, deaths, and rehospitalizations with HF or re-AMI (Table 1) . Table 3 reports the univariate hazard ratios of various factors that affected the outcome of MACE at 2 years. In multivariate analysis for predicting MACE at 2 years, significant independent predictors included age, Killip class above 1, eGFR, and NTproBNP.
Addition of ProSP to the model (model 2 in Table 3 In other models for prediction of the secondary composite endpoints of death and/or re-AMI (Table 4 ) and death and/or HF readmission (Table 5) , ProSP remained an independent predictor (p<0.0005 and p<0.001 respectively) of these endpoints, and in both models, ProSP showed added value to the clinical variables and NTproBNP (log likelihood χ 2 test p value <0.0001 for both composite endpoints).
Comparison with GRACE scores
The GRACE risk score (17) was originally derived for prediction of death and/or re-AMI at 6 months. We investigated the utility of the biomarkers NTproBNP and ProSP for prediction of death and/or re-AMI as well as other composite endpoints (MACE, death and/or HF).
GRACE scores and the biomarkers NTproBNP and ProSP were predictors of all composite endpoints in univariate analysis (Table 6 ). In multivariate analysis for MACE, death and/or re-AMI and death and/or HF at 6 months, both NTproBNP and ProSP demonstrated added value to the GRACE score, and in addition, ProSP showed added value to models with GRACE and NTproBNP for all composite endpoints analysed (p<0.0001 for all, Table 6 ). 
Reclassification Analysis
Category-free reclassification analysis (with no arbitrary cut-off probabilities) was employed as described by Pencina et al (19) to calculate the NRI (>0), for the effect of addition of NTproBNP or ProSP to the probabilities derived from the GRACE score in predicting the endpoints of death and/or re-AMI, MACE and death and/or HF (Table 7) . NTproBNP upclassified risk in all those with events for all these composite endpoints. However, it wrongly (and significantly) upclassified risk in those without events for the death and/or re-AMI and MACE endpoints, although correctly downclassifying risk in those without events for the death and/or HF endpoint. However, ProSP correctly downclassified risk in those without events for all composite endpoints. When ProSP was added to a composite risk score comprised of GRACE and NTproBNP, ProSP downclassified risk in those without events for the endpoints of MACE, and death and/or MI, and had no significant reclassification of those with the death and/or HF endpoint (Table 7) .
Decision tree analysis
In order to determine optimal cut-points for biomarkers, we constructed decision trees (using ProSP and NTproBNP levels and GRACE scores) to classify patients into survivors or those with the endpoint of death and/or re-AMI at 6 months. Using ProSP as an initial classifier (figure 3) a ProSP level under 72.08pmol/L and GRACE score under 137 defines a low risk group of patients (n=512, 44.6% of the total) in whom the event rate was 3.0%. Of these, only 3 patients (0.26%) had died within 6 months, and 1 (0.09%) had died within 30 days. ProSP levels above 121.6 pmol/L defined a high risk group of patients with a death/re-AMI rate of 37.7% and a death rate of 30.7% ( figure 3 ).
Discussion
In addition to the known effects of SP on pain and inflammatory pathways, SP may also have important effects on platelet aggregation (6),fibrinolysis (7) and strengthening of clot The association of SP with readmission with AMI may be due to effects of SP on platelet aggregation (6, 25) . Tachykinin family peptides (SP, endokinins A and B) are found in platelets (25) , and receptors on platelet membranes (NK1 and NK3) may mediate a modulatory positive paracrine feedback on platelet activation. NK1 inhibition reduces thrombus formation. SP also strengthens a clot after formation (8) , an effect which is dependent on NK1 receptors on leucocytes. This effect is more marked in those patients with a full length NK1 receptor (8) . In addition, SP may reduce tissue plasminogen activator activity and expression (7), hence potentially promoting thrombosis.
On the other hand, SP may also have some potentially beneficial roles in ischemia postconditioning (26) and in mobilisation of progenitor cells which may play a role in angiogenesis within ischemic tissue (27) . Our findings are hypothesis generating for investigating the role of SP on outcomes post-AMI, as it is uncertain whether beneficial effects of SP could be outweighed by the deleterious effects.
Limitations
Our findings are based on a population from a single centre, with 2 admitting hospitals, and should be verified in other larger populations. The rate of early revascularisation in our NSTEMI population was low and may not reflect the more contemporary invasive approach of revascularisation within 72 h of presentation. One advantage is that the relation of ProSP with poor outcomes would not have been confounded by higher early revascularisation rates.
Conclusions
Following AMI, circulating ProSP levels provide added value to the prognostic information determined by the GRACE score and the prognostically important biomarker NTproBNP. The ability of ProSP to predict recurrent AMI in addition to mortality may confer clinical utility on the tachykinin system in risk stratification after AMI. Heart Failure 112 (10) 13 (5) 19 (7) 28 (10) 52 (18) <0.0005
Re-AMI 149 (13) 29 (10) 35 (12) 33 (11) 52 (18) 0.021 
